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Abstract
Background: The aim of the study was to assess the impact of atrial fibrillation (AF) with 
and without the need for atrioventricular junction (AVJ) ablation on outcomes in patients 
undergoing cardiac resynchronization therapy (CRT).
Methods: A single center cohort of 200 consecutive CRT patients was divided into three 
groups: 1) AF with CRT pacing < 95% in which AVJ ablation was performed (AF-ABL,  
n = 40; 20%), 2) AF without the need for AVJ ablation (AF-nonABL, n = 40; 20%), 3) si-
nus rhythm (SR, n = 120; 60%). All patients were assessed before CRT implantation and at 
6-month follow-up. Positive clinical response to CRT was considered alive status without the need 
for heart transplantation and improvement ≥ 1 NYHA after 6 months. The comparative analysis 
among all study groups with respect to response-rate and long-term survival was performed.
Results: The 6-month response-rate in both AF-ABL and AF-nonABL was significantly 
lower than in SR (52.5 and 50 vs.77.5%, respectively; both p < 0.017), though there were 
no differences in baseline characteristics among study groups apart from higher baseline  
NT-proBNP levels in AF-ABL. However, after adjustment for this confounder, and despite 
optimal CRT pacing burden in study groups, the remote all-cause mortality during median 
follow-up of 36.1 months was significantly higher in AF-ABL than in SR (adjusted HR = 2.57, 
95% CI 1.09–6.02, p = 0.03). What is more, no difference in long-term survival between SR 
and AF-nonABL was observed.
Conclusions: Despite the improvement of CRT pacing burden and thus response-rate up to 
the level of AF subjects without the need for ablation, the long-term survival of AF patients 
requiring AVJ ablation remains still worse than in SR. (Cardiol J 2014; 21, 3: 309–315)
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Introduction
Cardiac resynchronization therapy (CRT) is 
an effective therapy in patients with symptomatic 
heart failure (HF), depressed left ventricular ejec-
tion fraction (LVEF), prolonged QRS complex and 
sinus rhythm (SR). It has been proven that CRT not 
only improves the functional capacity and quality of 
life, but also reduces mortality [1–5]. However, in 
a quite substantial percentage of HF patients CRT 
does not carry significant subjective and objective 
improvement [6]. Atrial fibrillation (AF) has been 
advocated as one of the potential factors linked 
to non-response in CRT recipients [7, 8]. This 
arrhythmia, which can be found in 30–40% of HF 
patients, contributes not only to the reduction of 
cardiac output but also to thromboembolic events. 
The profits of CRT in patients with AF have not yet 
been well established as majority of data on resyn-
chronization therapy comes from trials performed 
in subjects with SR. As a consequence, the current 
European Society of Cardiology (ESC) guidelines 
do recommend CRT implantation in AF subjects 
only with a low class of recommendation and level 
of evidence [9].
The effectiveness of CRT may be compromi-
sed in AF patients by diminished percentage of 
effective biventricular pacing, especially in subjects 
with poor control of ventricular rate during arrhyth-
mia. The ablation of atrioventricular junction (AVJ) 
is a potential solution in this subgroup, though data 
on the outcomes after this procedure are scarce. 
The aim of the study was to assess the impact of 
AF with and without the need for AVJ ablation on 
outcomes in HF patients treated with CRT.
Methods
Study population, follow-up
A single-center CRT registry has been de-
signed to prospectively enroll and analyze 200 
consecutive patients with first-time CRT device 
implantation. The study was conducted in a high 
volume tertiary care university hospital in Upper 
Silesia (a densely populated, urban area in southern 
Poland with over 4.6 million inhabitants). All inclu-
ded patients had drug — refractory symptomatic 
HF, New York Heart Association (NYHA) class III 
or IV, LVEF ≤ 35% and QRS duration > 120 ms.
All subjects were routinely assessed 1 week 
and 1 month after the implantation and subse-
quently every 3–6 months. Clinical assessment, 
verification of medication and CRT check-ups 
(percentage of biventricular burden, electrical 
properties of leads, battery status and arrhythmic 
episodes) were performed at every visit.
Whenever the low resynchronization burden 
(percentage of biventricular pacing — BVP% 
< 95) was identified in an AF patient at any of 
the CRT check-ups, drugs slowing AV conduction 
(mainly beta-blockers and digoxin) were initiated 
or up-titrated to achieve maximal tolerable doses. 
Patients in whom despite optimal pharmacotherapy 
for at least 3–6 months BVP% still remained low 
were qualified for AVJ ablation by the attending 
physician and electrophysiologist.
Prior to ablation, every patient was always 
informed in detail about the idea of the procedure 
and the consequent CRT dependency. Informed 
consent was obtained from all participants prior 
to their enrollment in the study. The study was 
complied with the Declaration of Helsinki and ap-
proved by the Ethical Committee.
Implantation of CRT device, pacemaker 
settings and AVJ ablation
Implantation of electrodes was performed 
in a standard way through a puncture of subcla-
vian vein or using a cut-down technique. Right 
ventricular leads (or defibrillation electrode in 
patients receiving a cardioverter-defibrillator) 
were positioned in the apex. Left ventricular 
(LV) leads were implanted through the coronary 
sinus and lateral or posterolateral veins were 
preferred as target implantation sites. Implanta-
tion of atrial leads into a right-atrial appendage 
was performed in all subjects. Type of implanted 
electrodes (unipolar/bipolar, active/passive fixa-
tion) was left at the discretion of the operator. 
In SR patients CRT devices were set into DDD 
mode with a minimum heart rate of 60 bpm. In 
AF subjects a minimum pacing rate of 60–70 bpm 
was set after the implantation. In patients who 
underwent AVJ ablation pacing rate was program-
med at 80 bpm for 3 weeks after the procedu-
re, and reprogrammed thereafter to 60–70 bpm. 
At baseline antiarrhythmic functions of CRT were 
programmed in an identical way in all subjects. In 
each patient the AV (except for patients with per-
manent AF) and interventricular delays were opti-
mized under echocardiographic guidance in order to 
obtain consistent ventricular capture, maximal LV 
filling time without concomitant truncation of the 
A-wave and to minimize inter- and intraventricular 
mechanical dyssynchrony [10, 11].
Radiofrequency AVJ ablation was performed 
in AF patients with low burden of CRT pacing if 
all attempts of drug therapy in order to slow the 
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ventricular rate finally failed (usually with beta-
-blocking agent and digoxin), but not earlier than 
1 month after CRT implantation. Ablation pro-
cedure was performed under local anesthesia 
by standard techniques in the electrophysiology 
cathlab. Two intracardiac electrodes were used: 
coronary sinus catheter (reference electrode used 
to confirm AV dissociation once conduction block 
had been created) and steerable ablation catheter. 
Acute success of AVJ ablation was 100%, though 
in 4 patients the second procedure had to be per-
formed after a mean of 2.5 months after the first 
ablation due to the recurrence of AV conduction.
Analyzed data 
The following parameters were collected at 
baseline and after 6 months of follow-up (in AF 
subjects with AVJ ablation 6 months after the ab-
lation): NYHA class, QRS duration (measured as 
the maximum QRS width in leads II, V1 and V6), 
N-terminal pro B-type natriuretic peptide (NT-
-proBNP) level, echocardiographic parameters 
including end-diastolic and end-systolic volumes 
(EDV and ESV), as well as LVEF assessed with 
the use of Simpson’s rule.
A positive clinical response to CRT was con-
sidered alive status without the need for heart 
transplantation and an improvement ≥ 1 NYHA 
class after 6 months of pacing. The electrophysio-
logists who performed CRT device implantation 
and AVJ ablation were not engaged in assessment 
of NYHA class.
A positive echocardiographic response to CRT 
was considered alive status without the need for 
heart transplantation and a ≥ 15% reduction in 
ESV after 6 months of pacing.
Statistical analysis
The continuous parameters were presented 
as median ± range. Categorical variables were 
expressed as numbers and percentages. For con-
tinuous data intergroup differences were tested 
with the ANOVA with Kruskal-Wallis rang test. 
The c2 test or Fisher’s exact test with Bonferroni 
correction to control type I error was used to 
compare categorical values. The Kaplan-Meier 
survival and the log-rank test were used to compa-
re survival probabilities. To assess the prognostic 
value of baseline data Cox regression analysis was 
performed, results of which were expressed as 
hazard ratio (HR) and 95% confidence interval (CI). 
A p value of less than 0.05 was considered stati-
stically significant. For multiple intergroup com-
parisons of baseline categorical parameters and 
response-rates, due to Bonferroni correction 
p values smaller than 0.017 were considered to in-
dicate statistical significance for each of the 3 com-
parisons. All statistical analyses were performed 
using the software package Statistica (version 6.0, 
StatSoft Inc., Tulsa, OK, USA and version 10.0).
Results
Study population
At the time of CRT device implantation 
120 patients were in SR, whereas 80 subjects 
had AF (42 patients permanent and 38 paroxy-
smal form of AF). In 40 patients with AF and 
low BVP% the AVJ ablation was performed 
after a mean of 5.5 (2–16) months after CRT 
implantation. Finally, three groups of patients 
with CRT were analyzed: 1) AF with low BVP% 
< 95% in which the successful AVJ ablation 
was performed (AF-ABL group, n = 40, 20%), 
2) AF without the need for AVJ ablation (BVP% 
≥ 95%, AF-nonABL group, n = 40, 20%), 3) SR 
group (n = 120, 60%).
The study groups did not differ with respect 
to baseline characteristics, such as age, gender, 
ischemic etiology, QRS duration, NYHA class and 
echocardiographic parameters (Table 1). However, 
when compared to SR, AF-ABL group had signifi-
cantly higher baseline NT-proBNP level (median 
1471.0 vs. 2932 pg/mL, p = 0.046).
Apart from significantly more frequent digoxin 
use in AF-ABL (p = 0.0001 vs. SR) and oral an-
ticoagulants in AF patients, the study groups did 
not differ with respect to pharmacological therapy 
after CRT implantation. At follow-up visits a global 
biventricular percentage was similar among the 
three groups (BVP% ≥ 95%).
Response to CRT
At 6 months of follow-up, a positive clinical 
response to CRT was demonstrated in 93 (77.5%) 
subjects in SR group, 21 (52.5%) in AF-ABL group 
(p = 0.0025 vs. SR group) and 20 (50%) in AF-
-nonABL group (p = 0.0009 vs. SR group). There 
was no statistical difference in clinical response-
-rates between AF-ABL and AF-nonABL groups 
(p = 0.82) (Fig. 1). A positive echocardiograp-
hic response to CRT was lower in AF-ABL 
group (19/40, 47.5%) and AF-nonABL group 
(21/40, 52.5%) than in SR subjects (72/120, 
60%), though the differences were not sig-
nificant (p = 0.41 for SR vs. AF-nonABL and 
p = 0.17 for SR vs. AF-ABL). Similarly, there was 
no statistically significant difference in echocar-
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diographic response-rate between AF-ABL and 
AF-nonABL groups (p = 0.65).
Survival
During a median follow-up of 36.1 (24.3–54.6) 
months the following number of patients died: 
26 (21.7%) patients in SR group, 13 (32.5%) in AF-
-nonABL group and 11 (27.5%) in AF-ABL group.
After adjustment for baseline confounder 
which was baseline NT-proBNP level, all-cause 
mortality was significantly higher in AF-ABL group 
than in SR group (adjusted HR = 2.57, 95% CI 
1.09–6.02, p = 0.03), but did not differ between 
SR and AF-nonABL groups (adjusted HR = 1.56, 
95% CI 0.62–3.92, p = 0.34) (Fig. 2).
Discussion
According to the ESC guidelines CRT may be 
considered to reduce the risk of HF worsening in 
patients with HF and permanent AF who present 
with NYHA function class III or IV, LVEF £ 35% 
and QRS duration ≥ 120 ms, who require pacing be-
Table 1. Baseline characteristics of study groups.
Sinus rhythm  
(n = 120)
AF-ABL  
(n = 40)
AF-nonABL  
(n = 40)
P P^ P#
Age [years] 59 (53–67) 62 (57–69) 57 (49–66) 0.21 0.78 0.82
Female* 32 (26.7%) 9 (22.5%) 9 (22.5%) 1.0 0.6 0.6
Diabetes mellitus type 2* 39 (32.5%) 16 (40%) 11 (27.5%) 0.24 0.39 0.56
Ischemic etiology* 57 (47.5%) 19 (47.5%) 18 (45%) 0.82 1.0 0.78
QRS interval [ms] 169.5 (155–185) 160 (140–190) 177 (160–200) 0.2 0.85 0.72
NYHA IV* 26 (21.7%) 14 (35%) 6 (15%) 0.04 0.09 0.36
LVEDV [mL] 263 (194–307) 227 (164–278) 237 (219–291) 1.0 0.24 1.0
LVESV [mL] 204 (147–244) 172 (116–204) 186 (171–218) 0.65 0.15 1.0
LVEDD [mm] 70 (66–79) 69 (64–77) 74 (67–78) 0.6 1.0 1.0
LVESD [mm] 60 (53–68) 56 (51–65) 62 (55–70) 0.21 0.25 1.0
LVEF [%] 24 (21–28) 23.5 (20–27.5) 24 (20–29) 1.0 1.0 1.0
NT-proBNP [pg/mL] 1471.0 2932 2410 1.0 0.046 0.795
(761.6–3323) (1390.5–4328) (889–4277)
Creatinine at admission [µmol/L] 94 (71–117) 98 (82.5–117) 91 (78–110.7) 0.89 0.795 1.0
Medication*:
Beta-blocker 119 (99.2%) 39 (97.5%) 38 (95%) 0.56 0.41 0.09
ACE-I/ARB 113 (94.2%) 37 (92.5%) 36 (90%) 0.69 0.71 0.37
Spironolactone 116 (96.7%) 36 (90%) 35 (87.5%) 0.72 0.09 0.03
Loop diuretic 109 (90.8%) 39 (97.5%) 38 (95%) 0.56 0.17 0.4
Digoxin 25 (20.8%) 21 (52.5%) 9 (22.5%) 0.06 0.0001 0.82
Amiodarone 26 (21.7%) 10 (25%) 15 (37.5%) 0.23 0.66 0.05
Vitamin K antagonists 10 (8.3%) 33 (82.5%) 27 (67.5%) 0.12 <0.001 <0.001
Continuous variables are presented as median (range); ABL — ablation; ACE-I/ARB — angiotensin-converting-enzyme inhibitors/angiotensin 
II receptor blockers; AF — atrial fibrillation; LVEDD — left ventricular end-diastolic diameter; LVESD — left ventricular end-diastolic diameter; 
LVEDV — left ventricular end-diastolic volume; LVESV — left ventricular end-systolic volume; LVEF — left ventricular ejection fraction;  
NT-proBNP — N-terminal pro B-type natriuretic peptide; NYHA — New York Heart Association classification; *p < 0.017 was considered  
significant due to Bonferroni correction; p — AF-ABL vs. AF-nonABL; ^p — SR vs. AF-ABL; #p — SR vs. AF-nonABL
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Figure 1. Percent of clinical cardiac resynchronization 
therapy (CRT)-responders in three groups of patients 
— with sinus rhythm and atrial fibrillation with and with-
out the need for ablation (SR; AF-ABL; AF-nonABL); 
#p < 0.017 vs. sinus rhythm.
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cause of an intrinsically slow ventricular rate or are 
CRT dependent as a result of AVJ ablation, or have 
ventricular rate £ 60 bpm at rest and £ 90 bpm 
on exercise [9]. However, there is still lack of 
randomized studies in patients with AF and data 
suggesting that these groups of patients may be-
nefit from CRT come from observational studies. 
What is more, it has been even suggested that 
the benefit of CRT in AF subjects may be limited 
only to those patients who were subjected to AVJ 
ablation [12].
Response to CRT in patients with SR and AF
Our results indicate that the functional 
improvement achieved by resynchronization 
therapy may be similar in AF patients regar-
dless of whether the ventricular rate can be 
adequately pharmacologically controlled or the 
AVJ ablation is required. Nevertheless, CRT 
response-rates of AF patients, irrespectively of 
the need for AVJ ablation, appeared to have been 
significantly worse when compared to subjects 
who were in SR.
Our results are concordant with other studies. 
Molhoek et al. [13] reported significantly lower 
percentage of responders in AF compared to the 
SR group (64% vs. 80%, p < 0.05) and no statistical 
difference in AF-ABL vs. AF-nonABL groups (71% 
vs. 54%, p = NS). Similarly, Tolosana et al. [14] 
observed comparable functional improvement after 
12 months of CRT in AF-ABL and AF-nonABL sub-
jects (58% vs. 59% CRT responders, p = NS) and 
a non-significant trend toward a lower percentage 
of responders in AF patients than in those with SR 
(59% vs. 70%, p = NS). On the contrary, Ferreira 
et al. [15] documented a significantly lower percen-
tage of responders among AF patients without AV 
node ablation when compared to those with SR, as 
well as those with AF and AVJ ablation (52% vs. 
79% vs. 85%, p = 0.008).
The main difference between previously pub-
lished data and our study is the qualification of AVJ 
ablation. Typically, 85% of pacing burden was used 
as a cut-off value for adequate biventricular pacing 
by other authors. However, according to the cur-
rent ESC guidelines, the minimum value of ≥ 95% 
should be used as optimal one [9]. What is more, 
CRT burden of less than 95% was associated with 
poor outcomes in several studies [16, 17]. The-
refore, in line with current ESC guidelines, some 
patients from previously published trials would 
have presently had indications for AVJ ablation due 
to suboptimal CRT pacing burden. Furthermore, 
during a long-term follow-up, the percentage of 
biventricular pacing in AF-nonABL groups in the 
aforementioned studies still remained suboptimal 
and lower than in patients who underwent ablation 
(87 ± 19% vs. 98 ± 6% in Ferreira et al. [15]; 82% 
vs. 100% in Molhoek et al. [13], and 92 ± 7% vs. 
100% in Tolosana et al. [14]). Of note is also that 
the BVP% varied from 82% to 96.5% in AF-nonABL 
subjects during a long-term follow-up [18]. Relati-
vely liberal criteria that were used for AVJ ablation 
qualification and consequently suboptimal burden 
of CRT pacing in non-ablated group could in turn 
lead to the risk overestimation in these groups. In 
our study, AF patients were treated in line with 
the current ESC guidelines, and long-term pacing 
burden was similar in ablated and non-ablated AF 
groups, which diminished the intergroup hetero-
geneity and substantially facilitated the analysis of 
the gathered data.
Survival
Previously published data indicates that AF 
is an independent predictor of mortality in HF pa-
tients. In the Framingham Study, the development 
of AF in HF subjects was associated with significan-
tly increased risk of death (1.6-fold in men and 2.7-
-fold in women) [19]. Also in CRT recipients it has 
been demonstrated than AF was an independent 
risk factor for death [20]. Tolosana et al. [21] docu-
mented a statistically significant higher probability 
of death from refractory HF at 12 months of follow 
up in patients with AF when compared to those 
Figure 2. Kaplan-Meier curves of cumulative survival in 
patients with sinus rhythm and atrial fibrillation with and 
without the need for ablation (SR; AF-ABL; AF-nonABL). 
Survival curves were adjusted for baseline N-terminal 
pro B-type natriuretic peptide level.
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who remained in SR (21% vs. 5.7%, p = 0.005). 
Permanent AF was an independent predictor of 
mortality from HF in this study. Ferreira et al. [15] 
showed significantly lower survival in AF pa-
tients without AV node ablation compared with SR 
(p < 0.001). In the same study the differences 
with respect to survival between SR vs. AF-ABL 
and AF-ABL vs. AF-nonABL were not significant 
(p = 0.120 and p = 0.070, respectively). Gasparini 
et al. [12] observed similar mortality in SR and AF 
patients (HR 0.90, p = 0.64), whereas comparing 
AF-ABL with AF-nonABL groups, total mortality 
was significantly lower in the first one (adjusted 
HR 0.26, p = 0.010). Smit et al. [7] described the 
new-onset AF, permanent AF and NT-proBNP 
levels as independent predictors of mortality in 
CRT patients.
The main finding of our study is that despite 
AVJ ablation the long-term survival of AF patients 
is significantly worse than in SR group. Our data 
indicate that in AF patients with inadequate ven-
tricular rate control AVJ ablation indeed leads to 
optimal CRT pacing burden and thus increase in the 
functional capacity and pre-specified response-rate 
up to the level of AF subjects without the need 
for ablation. However, the long term mortality in 
AF-ABL group is still significantly higher than in 
SR group. Therefore, it seems that CRT recipients 
with AF may have similar outcomes to patients 
with SR, until their heart rate can be adequately 
pharmacologically controlled. The rationale for this 
phenomenon is unknown. However, AF with a fast 
ventricular conduction may induce tachycardiomyo-
pathy and thus contribute to the aggravation of 
the preexisting HF, irrespectively of its primary 
etiology. Of note is also, that HF in this group of 
patients may already be so advanced and CRT in-
troduced so late that despite optimal biventricular 
pacing the process of unfavorable remodeling can 
be neither slowed nor reversed.
Another open issue is, whether the rapid 
ventricular conduction during AF that requires 
AVJ ablation is a risk factor or just a marker of 
a more advanced disease (e.g. being a sign of a highly 
elevated sympathetic tone due to HF progression). 
Large, prospective, randomized trials are needed 
to address and answer these queries and finally 
assess the role of AVJ ablation in AF patients 
undergoing CRT.
Limitations of the study
Our study is a non-randomized, single-center 
observational analysis, with all the drawbacks ty-
pical for such designed studies. Relatively small 
study groups may have led to underestimation 
of some important relations and differences in 
baseline characteristics and pharmacological the-
rapies which eventually could have created a bias. 
Another potential limitation may be differently 
programmed lower pacing rate in study groups, 
as well as the comparison of patients in SR with 
AF subjects regardless of the type of arrhythmia.
Conclusions
In conclusion, despite the improvement of 
CRT pacing burden and thus response-rate up 
to the level of AF subjects without the need for 
ablation, the long-term survival of AF patients 
requiring AVJ ablation still remains worse than 
in SR. A prospective, randomized clinical trial is 
necessary to assess the significance of AV node 
ablation in CRT-AF patients.
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